IL162203A0 - Indolinone derivatives useful as protein inase inhibitors - Google Patents

Indolinone derivatives useful as protein inase inhibitors

Info

Publication number
IL162203A0
IL162203A0 IL16220302A IL16220302A IL162203A0 IL 162203 A0 IL162203 A0 IL 162203A0 IL 16220302 A IL16220302 A IL 16220302A IL 16220302 A IL16220302 A IL 16220302A IL 162203 A0 IL162203 A0 IL 162203A0
Authority
IL
Israel
Prior art keywords
sup
derivatives useful
indolinone derivatives
protein
inase inhibitors
Prior art date
Application number
IL16220302A
Other languages
English (en)
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of IL162203A0 publication Critical patent/IL162203A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL16220302A 2001-12-27 2002-12-20 Indolinone derivatives useful as protein inase inhibitors IL162203A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34374601P 2001-12-27 2001-12-27
US34381301P 2001-12-27 2001-12-27
PCT/US2002/041252 WO2003057690A1 (en) 2001-12-27 2002-12-20 Indolinone derivatives useful as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
IL162203A0 true IL162203A0 (en) 2005-11-20

Family

ID=26993599

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16220302A IL162203A0 (en) 2001-12-27 2002-12-20 Indolinone derivatives useful as protein inase inhibitors

Country Status (22)

Country Link
US (3) US6686362B2 (ru)
EP (1) EP1458713B1 (ru)
JP (1) JP4363985B2 (ru)
KR (1) KR100965519B1 (ru)
CN (1) CN1290844C (ru)
AT (1) ATE302771T1 (ru)
AU (1) AU2002360753B2 (ru)
BR (1) BR0215360A (ru)
CA (1) CA2470480C (ru)
CO (1) CO5611126A2 (ru)
DE (1) DE60205776T2 (ru)
DK (1) DK1458713T3 (ru)
ES (1) ES2247411T3 (ru)
HK (1) HK1068886A1 (ru)
HU (1) HUP0500111A3 (ru)
IL (1) IL162203A0 (ru)
MX (1) MXPA04006271A (ru)
NO (1) NO327550B1 (ru)
NZ (1) NZ533219A (ru)
PL (1) PL208283B1 (ru)
RU (1) RU2316554C2 (ru)
WO (1) WO2003057690A1 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003259713A1 (en) * 2002-08-09 2004-02-25 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
US7105563B2 (en) 2003-10-24 2006-09-12 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
BRPI0617489A2 (pt) 2005-10-18 2011-07-26 Janssen Pharmaceutica Nv compostos, composiÇço e uso de ditos compostos para inibir a flt3 cinase
WO2007124322A1 (en) 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
DK2021335T3 (da) 2006-04-20 2011-09-05 Janssen Pharmaceutica Nv Heterocykliske forbindelser som C-FMS-kinasehæmmere
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
AU2007296740B2 (en) 2006-09-11 2012-09-27 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HUE045270T2 (hu) 2010-01-05 2019-12-30 Inst Nat Sante Rech Med FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
SG182480A1 (en) 2010-01-12 2012-08-30 Ab Science Thiazole and oxazole kinase inhibitors
CN104870454B (zh) 2012-08-07 2020-03-03 詹森药业有限公司 用于制备杂环酯衍生物的方法
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
TWI569799B (zh) 2012-09-21 2017-02-11 安羅格製藥股份有限公司 抑制組成型活性磷酸化flt3激酶的方法
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
JP2017523972A (ja) 2014-07-31 2017-08-24 アンセルム(アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル) Flt3レセプターアンタゴニスト
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
EP3359155A4 (en) 2016-11-02 2019-05-22 Arog Pharmaceuticals, Inc. CRENOLANIB FOR THE TREATMENT OF MUTATIONS ASSOCIATED WITH FLT3-MUTED PROLIFERATIVE DISEASES
AU2018269678A1 (en) 2017-05-17 2019-12-12 Biodol Therapeutics FLT3 inhibitors for improving pain treatments by opioids
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
US11713310B2 (en) 2020-07-20 2023-08-01 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
WO1999061422A1 (en) 1998-05-29 1999-12-02 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
ATE234830T1 (de) * 1998-12-17 2003-04-15 Hoffmann La Roche 4-alkenyl (und alkinyl)oxoindole als inhibitoren cyclinabhängiger kinasen, insbesondere cdk2
KR20010108063A (ko) 1998-12-31 2001-12-07 수젠, 인크. 단백질 인산화 효소의 조절 및 암의 화학적 치료를 위한3-헤테로아릴리데닐-2-인돌리논 화합물
DE19924401A1 (de) 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2257313T3 (es) 1999-08-27 2006-08-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Indolinonas sustituidas en calidad de inhibidores de tirosina quinasa.
EP1222187B1 (en) 1999-10-06 2004-09-22 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
UA75054C2 (ru) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Замещенные в положении 6 индолиноны, их получение и их применение как лекарственного средства
DE19949209A1 (de) 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2001042243A2 (en) 1999-12-08 2001-06-14 Advanced Medicine, Inc. Protein kinase inhibitors
SI1255752T1 (sl) 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
US6635640B2 (en) 2000-06-30 2003-10-21 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
WO2002016351A1 (en) 2000-08-18 2002-02-28 Cor Therapeutics, Inc. Quinazoline derivatives as kinase inhibitors
EP1349852A2 (en) 2000-12-20 2003-10-08 Sugen, Inc. 4-(hetero)aryl substituted indolinones
AU2003259713A1 (en) * 2002-08-09 2004-02-25 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
US20050171182A1 (en) 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases

Also Published As

Publication number Publication date
HUP0500111A2 (hu) 2005-07-28
DE60205776D1 (en) 2005-09-29
NO327550B1 (no) 2009-08-10
KR20040070283A (ko) 2004-08-06
US20060142281A1 (en) 2006-06-29
HUP0500111A3 (en) 2009-10-28
CN1290844C (zh) 2006-12-20
RU2004122918A (ru) 2005-03-27
CA2470480A1 (en) 2003-07-17
US20040198804A1 (en) 2004-10-07
RU2316554C2 (ru) 2008-02-10
US7060703B2 (en) 2006-06-13
MXPA04006271A (es) 2004-10-04
KR100965519B1 (ko) 2010-06-23
CA2470480C (en) 2010-12-14
EP1458713B1 (en) 2005-08-24
US20030171378A1 (en) 2003-09-11
DK1458713T3 (da) 2005-10-31
HK1068886A1 (en) 2005-05-06
ES2247411T3 (es) 2006-03-01
PL208283B1 (pl) 2011-04-29
BR0215360A (pt) 2004-12-14
AU2002360753A1 (en) 2003-07-24
NZ533219A (en) 2005-10-28
PL369602A1 (en) 2005-05-02
NO20042926L (no) 2004-07-08
WO2003057690A1 (en) 2003-07-17
EP1458713A1 (en) 2004-09-22
AU2002360753B2 (en) 2008-08-21
JP4363985B2 (ja) 2009-11-11
JP2005514420A (ja) 2005-05-19
CO5611126A2 (es) 2006-02-28
ATE302771T1 (de) 2005-09-15
DE60205776T2 (de) 2006-06-14
US6686362B2 (en) 2004-02-03
CN1608063A (zh) 2005-04-20
US7223783B2 (en) 2007-05-29

Similar Documents

Publication Publication Date Title
HK1068886A1 (en) Indolinone derivatives useful as protein kinase inhibitors
IL171976A0 (en) Indazole, benzisoxazole, and banzisothiazole kinase inhibitors
MY130363A (en) "pyrrole substituted 2-indolinone protein kinase inhibitors"
CA2366932A1 (en) Cyclic protein tyrosine kinase inhibitors
MY126235A (en) 3-(4-amidopyrrol-2-ylmethylidene) -2- indolinone derivatives as protein kinase inhibitors.
MX2007001986A (es) Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
IL110131A0 (en) Arylidene and heteroarylidene oxindole derivatives, their preparation and pharmaceutical compositions containing them
TW200621751A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
ATE339418T1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
IL173348A0 (en) Thienopyridine and furopyridine kinase inhibitors
CA2387351A1 (en) Indole derivatives as tyrosine kinase inhibitors
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
AU2464601A (en) Tricyclic protein kinase inhibitors
MXPA04004107A (es) Moleculas pequenas para el tratamiento del crecimiento celular anormal.
YU4903A (sh) N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
MXPA02010759A (es) Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa.
MXPA04001977A (es) Antagonistas v de receptor ccr-3.
AU2002366563A1 (en) Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders
UA86083C2 (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors